This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2006 by Eugonia.
Recruitment status was:  Recruiting
Information provided by:
Eugonia Identifier:
First received: December 22, 2006
Last updated: December 28, 2006
Last verified: December 2006
The purpose of this study is to compare the efficacy of two controlled ovarian stimulation protocols, the GnRH agonist protocol, widely known as the "long" protocol, and the flexible GnRH antagonist protocol, in terms of pregnancy rates and embryological data, in infertile patients receiving IVF treatment.

Condition Intervention Phase
Infertility Drug: Arvekap 0.1 mg (Triptorelin, Ipsen, France) Drug: Ganirelix 0.25 (Orgalutran, Organon, The Netherlands) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial Comparing the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation in Normal Responders

Resource links provided by NLM:

Further study details as provided by Eugonia:

Primary Outcome Measures:
  • Ongoing pregnancy per embryo transfer

Secondary Outcome Measures:
  • Biochemical pregnancy per embryo transfer
  • Clinical pregnancy per embryo transfer
  • Embryological data

Estimated Enrollment: 300
Study Start Date: September 2005
Estimated Study Completion Date: June 2007
Detailed Description:

The formulation of controlled ovarian stimulation protocols is one of the primary reasons for the successful development of IVF. The "long" GnRH agonist protocol, also known as the gold standard, has been widely used with considerable success. More recently, on the other hand, GnRH antagonist provide a new promising approach for endogenous gonadotrophin suppression by blocking the GnRH receptor. There is conflicting data in the literature regarding the relative merits of the two ovarian stimulation protocols.

COMPARISON: Pregnancy rates and embryological data will by assessed in IVF patients treated with either the "long" GnRH agonist (Arvekap) or the flexible GnRH antagonist (Ganirelix) protocol.


Ages Eligible for Study:   21 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-39 years
  • Body mass index 18-29 kg/m2
  • Menstrual cycle from 24-35 days
  • Normal basal FSH (<10 IU/ml)
  • Normal basal LH (<10 IU/ml)
  • Normal basal estradiol (<80 pg/ml)

Exclusion Criteria:

  • Poor responder patients
  • Polycystic ovaries
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00417183

Contact: Tryfon Lainas, PhD 00302107236333

Eugonia Recruiting
Athens, Greece, 11528
Contact: Tryfon Lainas, PhD    00302107236333   
Sponsors and Collaborators
Principal Investigator: Tryfon Lainas, PhD Eugonia
  More Information

Publications: Identifier: NCT00417183     History of Changes
Other Study ID Numbers: long vs flexible
Study First Received: December 22, 2006
Last Updated: December 28, 2006

Keywords provided by Eugonia:
GnRH antagonist
GnRH agonist
Long protocol

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Triptorelin Pamoate
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on September 20, 2017